Baseline SUVmax may have prognostic value in patients with follicular lymphoma

Among patients with follicular lymphoma, the maximum standardized absorption value (SUVmax) recorded for 2-deoxy-2-fluoro-D-glucose (18F-FDG) can predict which patients have a low risk of long-term relapse. , according to a study published in Cancers.

Follicular lymphoma is the most commonly diagnosed non-Hodgkin lymphoma. While the prognosis of patients with follicular lymphoma has improved over the past decades, about 1 in 5 patients have a short-term relapse, while the majority of patients are likely to have a long-term relapse.

In addition, it is difficult to identify patients at high risk of long-term relapse. For this retrospective cohort study, researchers assessed whether SUVmax on baseline PET / CT had prognostic value in patients with follicular lymphoma.


Read on

Overall, data from 94 patients were included in this study. Patients were divided into 1 of 2 groups: group A (34 patients; 36.2%), where patients had a basal SUVmax of 6 or less, or group B (60 patients; 63.8%), where patients had a basal SUVmax score greater than 6.

The overall 5-year progression-free survival (PFS) rate was 87.5%. The 2-year PFS rates were 97% in groups A and B. Patients in group B, however, had an improved 5-year PFS rate (95%) compared to group A (75%; P = .005).

In the absence of other risk factors evaluated, a benefit of PFS was confirmed: patients without risk factor in group A had a rate of 5-year PFS of 73% compared to 83% among patients in group B with at least 2 risk factors.

“In conclusion, our data demonstrated the independent prognostic role of baseline SUVmax as a predictor of PFS, particularly in patients with low-risk follicular lymphoma,” the authors wrote. “Even without other risk factors, patients with low tumor metabolic activity had a higher likelihood of long-term relapse.”

Reference

Assanto GM, Ciotti G, Brescini M, et al. A high basal maximum standardized absorption (SUVmax) value in follicular lymphoma identifies patients with a low risk of long-term relapse. Cancers (Basel). 2021; 13 (12): 2876. doi: 10.3390 / cancers13122876

Source link

About Myra R.

Myra R.

Check Also

Waters Rankings 2021: Best Vendor-Side Order Management System (OMS) Provider – Bloomberg

Waters 2021 Ranking: Best Vendor-Side Order Management System (OMS) Provider – Bloomberg – WatersTechnology.com Phil …

Leave a Reply

Your email address will not be published. Required fields are marked *